PFE/MTSR—As a matter of policy, most companies won't comment on matters under litigation. You don't want to inadvertently say something that your adversary might use against you in court. Hence, Bourla’s non-answer regarding MTSR on PFE's 3Q25 CC was par for the course.
p.s. I'm surprised that PFE raised its offer while its request for a TRO is pending at the Delaware Chancery Court.
I just got around to reading the PFE transcript and in response to a question about a new oral phase 2 drug they admitted it is indeed a stat6 inhibitor that was previously in stealth mode. This puts them about even with KYMR and ahead of the SNY partnered program and ENTA
Market Data 
Markets 
AI
